FDA panel approves over-the-counter diet pill
NBC VIDEO |
Doctor offers perspective on OTC diet pill Jan. 24: “Today” show’s Campbell Brown talks with obesity specialist Dr. Judith Korner of NY Presbyterian/Weill Cornell Medical Center about the new weight-loss pill. Today show |
LIVE QUOTE |
Quotes delayed 15+ min. |
Diet and fitness videos |
Helpful hints to slim down your hubby Dec. 22: Liz Vaccariello, author of “The Flat Belly Diet! For Men,” talks to the TODAY hosts about helping your hubby drop that extra fat that accumulates around the middle. |
Smart Fitness — By Jacqueline Stenson |
6 gifts fit for the gym rat on your list Searching for a gift for the exercise enthusiast on your list? Whatever the sport or activity, we have ideas that are fun, functional and in a range of prices to help keep you fiscally fit. |
Potential for abuse
On Monday, FDA panel members questioned whether consumers would be able to distinguish Alli from non-approved dietary supplements also sold as weight-loss aids. They also expressed concern about its effect on vitamin intake. Half of the patients enrolled in trials of the drug failed to understand labeling directions that they should take supplemental vitamins at least two hours before or after using the pills.
The drug also could cause problems for organ transplant patients taking the drug cyclosporine as well as those on warfarin, a blood thinner. The drug’s label would warn such patients against taking the weight-loss pill.
When taken with meals, orlistat blocks the absorption of about one-quarter of any fat consumed. That fat — the equivalent of about 150 to 200 calories — is passed out of the body in stools, which can be loose or oily as a result. Other side effects include gas, incontinence and oily spotting. About half of patients in trials experienced such side effects, the company said.
Furthermore, just 35 percent of diabetes patients in a study correctly stated that the drug was inappropriate for them, according to FDA documents.
Those results worried FDA reviewers, who questioned the risk of selling the drug directly to consumers “without the principal involvement of a learned intermediary,” or prescribing doctor.
The reviewers also expressed concern about the increased potential for abuse or misuse of a prescription-free version of the drug, especially among bulimics or binge-eaters who could develop vitamin deficiencies due to chronic use.
The company said there was a “very low” potential for abuse, with only four published reports of bulimics using the drug. More than 22 million people worldwide have used orlistat in prescription form.
British-owned GlaxoSmithKline’s U.S. operations are based in Philadelphia and Research Triangle Park, N.C.
- Discuss Story On Newsvine
-
Rate Story:
View popularLowHigh - Instant Message
MORE FROM FITNESS |
| Add Fitness headlines to your news reader: |
Resource guide


